Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

IMPORTANCE: Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been repor...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Oncol
Päätekijät: Reardon, David A., Brandes, Alba A., Omuro, Antonio, Mulholland, Paul, Lim, Michael, Wick, Antje, Baehring, Joachim, Ahluwalia, Manmeet S., Roth, Patrick, Bähr, Oliver, Phuphanich, Surasak, Sepulveda, Juan Manuel, De Souza, Paul, Sahebjam, Solmaz, Carleton, Michael, Tatsuoka, Kay, Taitt, Corina, Zwirtes, Ricardo, Sampson, John, Weller, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2020
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7243167/
https://ncbi.nlm.nih.gov/pubmed/32437507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.1024
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia